The strong chimerism data and planned Phase 3 initiation this month de-risk TSC-101's path to pivotal trial. Monitor for first patient enrollment announcement and any KOL event commentary on market opportunity.
TCRX drugs
TCRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 22 $0.8651entry
- T+1 · 5mo ago +6.46%α +7.91% · $0.9210
- T+5 · 5mo ago +11.99%α +14.06% · $0.9688
- T+20 · 4mo ago +5.75%α +5.89% · $0.9148
- T+60 · 2mo ago −62.86%α −64.61% · $0.3213
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics presented positive Phase 1 Cohort C data for TSC-101, showing 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, with all 5 patients assessed after a second infusion also achieving complete chimerism. The company remains on track to enroll the first patient in the pivotal Phase 3 ALLOHA-2 study this month, supporting a bullish catalyst for this clinical-stage biotech.
Key Facts
- 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first TSC-101 infusion
- All 5 patients assessed after second infusion achieved complete chimerism
- 93% of patients responded with decreasing recipient chimerism in higher-risk population vs Cohort A and control
- One TP53-mutated AML patient remained in complete donor chimerism 6 months post-HCT
- Manufacturing success rate ~90% (17/19) with commercial-ready process
- Company on track to enroll first patient in Phase 3 ALLOHA-2 study this month
- Safety profile consistent with Cohort A; adverse events consistent with post-HCT expectations
Financial Impact
No financial data provided; clinical-stage company with no approved products or revenue
Risk Factors
- Phase 3 trial may fail to replicate Phase 1 efficacy or safety results
- Competition from other post-transplant relapse prevention therapies
- Company has no approved products and will need additional financing to complete Phase 3
- Small sample size (14 dosed patients) limits statistical reliability of current data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3315162 |
Track record
15 reports on TCRX
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers